By Super User on Friday, 06 November 2026
Category: NLS Blog

Risk-Based Quality Management in Clinical Registries

Improving Data Quality and Participant Retention

How can clinical research teams effectively maintain data quality and participant engagement across large, decentralized registries? Risk-based quality management (RBQM) is a practical strategy that involves using data-driven risk identification and targeted interventions to develop targeted data monitoring procedures that address emerging issues before they compromise study outcomes.

The PD GENEration registry (PDGENE), led by the Parkinson’s Foundation, demonstrates how this approach can support participant retention and data completeness in complex clinical research programs. Navitas Life Sciences applied RBQM strategies to identify sites with elevated loss-to-follow-up (LTFU) rates and implemented site-specific interventions and operational improvements to address this metric during the Registry’s whole genome sequencing (WGS) collection phase.

Why Is Risk-Based Quality Management Important in Clinical Registries?

Clinical registries generate valuable longitudinal data that advance disease research and improve understanding of patient populations. However, maintaining consistent data quality across thousands of patients, multiple sites and decentralized workflows can be challenging.

PDGENE participants enroll through local clinical sites or remote pathways. Study activities involve sample collection, genetic testing and genetic counselling, which can be completed in-person at a local site or remotely. Delays in sample collection and shipment and bottlenecks in scheduling of genetic counselling can lead to incomplete procedures and difficulties with maintaining participant contact. Missing data and participant loss to follow-up can become critical issues for clinical registries.

RBQM in clinical research addresses these challenges by prioritizing critical-to-quality data and processes, monitoring performance trends and directing resources toward areas of greatest risk. Rather than applying uniform oversight across every site, research teams can focus on specific indicators that may affect data reliability or study completion.

Centralized monitoring plays an important role in this process. By analyzing aggregated data, performance indicators and site-level trends, research teams can identify emerging risks, prioritize reviews and implement targeted interventions. For decentralized clinical research, this approach can help teams recognize participant attrition earlier and focus support where it is most needed.

These principles align with the broader emphasis on proportionate risk-based quality management described in ICH E6(R3) Good Clinical Practice guidance.

PD GENEration: Applying RBQM to a Decentralized Registry

PD-GENE is an international Parkinson’s disease research registry genetic repository initiative led by the Parkinson’s Foundation. The program offers genetic testing and genetic counseling to people living with Parkinson’s disease while building a resource to support research into the genetic factors associated with the condition.

Navitas Life Sciences supports the program through clinical operations and data management and has been in partnership for more than five years. Given the Registry’s scale, multiple participating sites and decentralized operational model, maintaining participant engagement and minimizing loss to follow-up were important priorities.

Following a protocol amendment in March 2024, whole genome sequence testing was initiated for study participants. The team needed an effective way to identify participants who had not completed required study activities, recognize sites experiencing higher attrition and implement appropriate mitigation strategies.

How Navitas Implemented a Risk-Based Quality Management Approach

1. Identifying Critical Data and Activities
The team evaluated the PDGENE workflow to identify critical study activities related to program quality that could be vulnerable to risk. This review included timely sample collection and genetic counseling and participant engagement through key study milestones.
Identifying and defining these prioriy activities helped focus quality reviews on areas most relevant to data completeness and successful study completion.

2. Leveraging Centralized Monitoring and Trend Analysis
Monthly participant-level tracking reports were developed to provide visibility into site performance and emerging risks. The reports helped the team identify incomplete activities, assess loss-to-follow-up trends and determine which sites required additional support.
By monitoring LTFU rates at the site level, the team could identify patterns requiring investigation, distinguish potential site-level challenges from individual participant delays and prioritize corrective action accordingly.

3. Developing Targeted Site Communication
Tailored communication strategy with research sites was developed by assessing and evaluating site metrics and trends. The communication approach combined site-specific guidance with participant-level follow-up to address incomplete data and support each site to minimize participant attrition.
This connected risk identification with practical intervention, making quality management a continuous data-driven process rather than a retrospective exercise.

Results: Reducing Loss to Follow-Up Through Targeted Monitoring

The growing complexity The results demonstrated measurable improvements in participant retention during the WGS phase.

In February 2025, 1,876 participants were enrolled in the WGS protocol with an overall LTFU rate of 6.1% across participating sites.

By August 2025, enrollment had increased to 5,454 participants while the overall LTFU rate declined to 3.6%.

This represents a reduction of 2.5 percentage points or approximately a 41% relative reduction in the overall LTFU rate.

Site-level analysis provided additional insight. In February 2025, nine sites had LTFU rates above 10%. By August 2025, five of these nine sites had reduced their rates to below 10%.

These findings highlight the operational value of combining centralized monitoring, site-level performance tracking and targeted interventions. Although the improvement cannot be attributed exclusively to RBQM, the approach helped identify higher-risk sites and guide focused mitigation efforts as enrollment expanded.

Five Lessons for Improving Clinical Registry Data Quality

The PD-GENE experience offers practical lessons for sponsors, registry owners and contract research organizations.

1. Monitor trends related to participant progression, not just missing data. Tracking milestones helps identify where delays and incomplete activities originate.

2. Use centralized monitoring to prioritize resources. Observation of study trends can reveal site-level patterns that may be difficult to identify through individual case reviews.

3. Turn risk signals into action. Targeted communication and participant-level follow-up help translate monitoring insights into practical interventions.

4. Review risks continuously. Enrollment growth, protocol changes and evolving workflows can introduce new risks that require regular reassessment.

5. Connect participant engagement with data quality. Clear instructions, timely follow-up and appropriate site support can help participants complete required activities and contribute to more complete datasets.

The Future of RBQM in Clinical Research

Clinical research increasingly incorporates decentralized participation, longitudinal data collection and complex registry designs. Quality management must adapt alongside these evolving study models.

Risk-based quality management provides a structured framework for identifying critical risks, monitoring performance and directing oversight proportionately. When embedded in clinical operations, it can help teams identify emerging issues earlier and make monitoring more purposeful.

The PD-GENE experience illustrates how centralized monitoring, participant-level tracking and targeted site communication can support efforts to improve participant retention and registry data completeness.

For organizations managing complex clinical registries, high-quality data depends not only on what is collected but also on how effectively risks are identified and addressed throughout the research lifecycle.

Navitas Life Sciences supports clinical research programs through data-driven clinical operations and data management approaches designed to strengthen oversight, improve operational coordination and support reliable research data.

Frequently Asked Questions

How does centralized monitoring improve clinical data quality?
Centralized monitoring uses aggregated data, performance indicators, and trend analysis to identify emerging risks across sites. It helps research teams prioritize reviews and implement targeted interventions.

How can clinical research teams reduce loss to follow-up?
Teams can monitor participant progress, identify sites with elevated attrition, provide timely reminders, improve communication, and offer site-specific support based on monitoring findings.

Why is RBQM valuable for decentralized clinical research?
Decentralized research involves multiple participant pathways and remote activities. RBQM helps teams identify operational risks, monitor completion trends, and focus support where it can make the greatest difference.

Planning a clinical registry or looking to optimize an existing one?
Connect with Navitas Life Sciences to discuss your clinical research requirements and explore how our clinical operations and data management expertise can support your program

Our latest article, published in Applied Clinical Trials, explores how a flexible CRO partnership, Quality by Design (QbD) and risk-based oversight can help address the complex operational needs of growing biotech companies.

Sowmya Kaur
Executive Vice President, Clinical
Navitas Life Sciences

Janel Shelton-DeMagnus
Senior Director, Clinical Operations
Navitas Life Sciences

Ndimuangu Nchotou Hilton
Senior Clinical Research Associate
Navitas Life Sciences

Read Now!

Event

Celebrating Focused Ultrasound 2026

Date: November 11–13, 2026
Venue: Hilton McLean Tysons Corner, McLean, Virginia, USA | Virtual

Meet us at ‘ Celebrating Focused Ultrasound 2026’, taking place November 11–13 in McLean, Virginia, and online. The event brings together the focused ultrasound community to explore advances in this innovative, non-invasive technology and its potential to transform patient care.

Learn more here



Learn more about our services and solutions by reaching out to us at This email address is being protected from spambots. You need JavaScript enabled to view it..

« Return to blog

Leave Comments